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Myopia is an emerging public health issue with potentially significant economic and social impact in 2 
populations especially from East Asia. However, many uncertainties around myopia and its clinical 3 
management. The International Myopia Summit workgroup was convened by the Singapore Eye 4 
Research Institute, the World Health Organization (WHO) Regional Office for the Western Pacific 5 
and the International Agency for the Prevention of Blindness (IAPB) in 2019. The aim of this 6 
workgroup was to summarise available evidence, identify gaps or unmet needs, and provide 7 
consensus on future directions for clinical research in myopia. In this review, amongst the many 8 
‘controversies in myopia’ discussed, we highlight three main aspects: First, development of clinical 9 
interventions for the prevention of ocular elongation and pathologic myopia are needed, and may 10 
require multifaceted research targeting multiple sites, including the Bruch’s membrane, choroid and 11 
sclera.  Second, clinical myopia management requires cooperation between optometrists and 12 
ophthalmologists to provide patients with holistic care, and a tailored approach that balances risks and 13 
benefits of treatment by utilising both optical and pharmacological interventions. Third, the diagnosis 14 
and management of myopia complications may be improved through collaboration between 15 
clinicians, researchers and industry. There is an unmet need to develop new imaging modalities for 16 
both structural and functional analyses and to establish normative databases for myopia in the long 17 
term.  In conclusion, the workgroup’s call to action advocated for a paradigm shift towards a 18 











Myopia is increasingly recognised as an emerging public health issue with significant economic 2 
burden particularly in East Asia.[1-5] The awareness of myopia and it impact has led to the 3 
implementation of public health interventions, the study of myopia control therapies and research into 4 
the treatment of myopia-related complications.[6] However, there are several unresolved questions 5 
with regards to the clinical management of myopia and pathologic myopia. Thus, the International 6 
Myopia Summit (IMS) workgroup was convened in 2019, supported by the World Health 7 
Organisation (WHO) and the International Agency of Prevention of Blindness (IAPB).  8 
 9 
The main aim of this workgroup was to discuss ‘controversies’ surrounding myopia, identify unmet 10 
needs in myopia research and its clinical management, and provide suggestions for future 11 
development in the field of myopia – Supplementary Table 1. The composition of the workgroup 12 
consisted of representatives from 20 international organizations renowned for myopia prevention, 13 
research and/or clinical management. Members of the workgroup comprised public health officials, 14 
optometrists, ophthalmologists and researchers – Supplementary Table 2. The definitions of myopia 15 
used followed recent consensus,[6-9] to ensure consistency for this workgroup meeting – Table 1. 16 
 17 
In this review, we included published literature from a non-systematic review of available evidence 18 
from the last 20 years up to July 2019 in MEDLINE, EMBASE and Cochrane Library, using the 19 
search terms “myopia”,“high myopia”, “pathologic myopia” alone or in combination with 20 
“prevalence”, “epidemiology”, “diagnosis”, “treatment”, “imaging”, “control”,“prevention”, 21 
“optical”, “spectacles”, “atropine”, “contact lens” and “orthokeratology”. The reference lists from 22 
articles identified by this search strategy were also used to include other relevant publications. While 23 
publications on randomized clinical trials were prioritized, we also included highly regarded or 24 
highly-cited publications, such as review articles and meta-analyses. Here, we present discussions on 25 
three ‘controversies’ in the clinical management of myopia, highlighted by the workgroup as aspects 26 
that may require further collective focus – Figure 1.  27 
 5 
 1 
Table 1: Definitions of Myopia used in this review as previously defined [6-9]  2 
Term Definition 
Myopia Spherical equivalent refractive error ≤ –0.50 diopter   
High myopia 
(without pathology) 




A vision-threatening condition occurring in people with myopia, usually 
high myopia that comprises diffuse or patchy macular atrophy with or 
without lacquer cracks, macular Bruch's membrane defects, myopic 
choroidal neovascularisation and Fuchs spot. 
Pathologic myopia Excessive axial elongation associated with myopia that leads to structural 
changes in the posterior segment of the eye (including posterior staphyloma, 
myopic macular degeneration, myopic traction maculopathy, and high 
myopia-associated optic neuropathy) and that can lead to loss of best-
corrected visual acuity. 
 3 
Controversy 1: Should research in myopia treatments focus on preventing the development of 4 
pathologic myopia rather than prevention of myopia progression? 5 
 6 
There is increasing awareness that myopia is not just a refractive error that can be “reversed” by 7 
optical aids or refractive surgery. Myopia may progress to pathologic myopia, a potentially blinding 8 
condition due to complications such as retinal detachment, myopic maculopathies and glaucoma.[10] 9 
However, current clinical management of myopia is focused on its control and reducing myopia as a 10 
refractive error, rather than interventions to prevent the development of pathologic myopia and its 11 
complications.[10 11] Given this context, two important aspects were highlighted and discussed:  12 
 13 
‘Does controlling myopia in childhood, prevent the development of pathologic myopia in adulthood?’ 14 
 6 
Pathologic myopia (PM) is a sight threatening condition that includes myopia macular degeneration 1 
(MMD), myopic traction maculopathy, myopic choroidal neovascularization (mCNV) and myopia-2 
associated optic neuropathy.[8 10]  Posterior staphyloma (PS), an outward protrusion of all layers of 3 
the posterior eye globe, is a hallmark lesion of PM.[11] The prevalence of PM is closely correlated 4 
with the severity of myopia.[12]  The Guangzhou twin eye study demonstrated that earlier age at 5 
myopia onset was associated with higher myopic refractive error at 18 years old .[13]  Current myopia 6 
control options can reduce progression by 50% and specifically, among children with age of onset at 8 7 
years old, myopia control would reduce their mean refractive error from -6D to -3D. This level of 8 
myopia control would significantly reduce the risk of PM from 30% to 5%.[14]  9 
 10 
Conversely, PM is a complex condition with multiple non-modifiable risk factors other than axial 11 
length (AL), such as age, gender and genetics.[10] With pharmaceutical treatments, AL reduction is 12 
limited. Specifically in the ATOM and LAMP studies, AL increased by +0.41mm and +0.36mm in 13 
the 0.01% atropine groups, respectively, compared to +0.38mm and +0.4mm with placebo.[15-18]  14 
The second year follow up of LAMP Study did however report significant reduction in axial 15 
elongation when children on placebo, were switched to 0.05% Atropine in the second year (0.15 vs 16 
0.43 mm, P< 0.001 in year 2 and year 1, respectively.[19] Furthermore, eyes with shallow PS may 17 
have a higher frequency of mCNV[20], suggesting that the risk of mCNV may not be closely 18 
correlated with AL. Age is another important risk factor. PM and PS do not occur in children with 19 
high myopia without pathology.[21 22]  Men in general have longer AL than women[23], but a higher 20 
prevalence of MMD and mCNV is observed in females in multivariable analyses.[24 25] Lastly, 21 
genome wide association studies have identified single nucleotide polymorphisms (SNPs) for 22 
refractive error[26], while the SNPs specific for PM are still unknown.[27] However, it remains 23 
unclear if slowing myopia progression in individuals with high genetic risk will be effective in 24 
preventing PM. 25 
 26 
 7 
‘A potential treatment target: Is the Sclera and choroid, or Bruch’s membrane a primary site of 1 
pathogenesis in pathologic myopia?’ 2 
Ophthalmoscopic features of axial myopia suggest a significant contribution of the Bruch’s membrane 3 
(BM) to several pathologic features including lacquer cracks (cracks in the BM), patchy/macular 4 
atrophy (both are BM defects), mCNV (which arise from a break of the BM) and parapapillary 5 
gamma zone (a result of the temporal shift and widening of the optic nerve head–related BM 6 
opening).  Histologically, BM defects in congenital colobomata and toxoplasmotic scars are 7 
associated with scleral staphyloma.[28]  Both choroidal and scleral volume are not associated with 8 
AL, but BM increases in volume with AL.[29]  This suggests that BM may have an active role in the 9 
process of axial elongation.  A hypothesis for the role of BM in the process of myopization states that 10 
axial elongation occurs by the production of and elongation of the BM in the equatorial region.[30]  11 
This explains the decrease in retinal pigment epithelium density and retinal thinning at the equator.[31 12 
32] Also, the compression of the choroid against the sclera by the expanding BM results in choroidal 13 
thinning.[30]  Enlargement of the BM opening and development of macular BM defects may be 14 
explained by the tension in BM in the coronal direction.[30]  Thus, BM may be more than just an 15 
almost invisible double basal membrane with some collagen and elastin in between.  Further evidence 16 
to support this hypothesis was demonstrated in a guinea pig model of myopia, in which intraocular 17 
injection of antibodies to amphiregulin, a member of the epithelial growth factor family that regulates 18 
the production of BM, was shown to decrease axial elongation in a dose dependent manner.[33 34] 19 
 20 
There is equally strong evidence for the sclera and choroid as the primary sites of pathology in PM.  21 
In both mammalian models and in human studies, myopia development is associated with rapid 22 
scleral thinning and tissue loss.[35-37]  Remodelling of the sclera is a major feature in the guinea pig 23 
model of myopia in particular.[38]  In terms of biomechanics, scleral biomechanical properties varies 24 
with the severity of myopia, and focal areas of weakness in the sclera can be found in the myopic 25 
eye.[39] Choroidal thinning is closely associated with increasing levels of myopia and MMD[40 41] 26 
and in the chicken myopia model, choroid thickness is negatively correlated with myopia.[42]  Scleral 27 
 8 
crosslinking as a means to stop scleral growth has been extensively investigated, but clinical 1 
application has been limited by a lack of safe and effective methods for applying ultraviolet A 2 
radiation and chemicals to the posterior sclera.[43 44]  Lastly, scleral regenerative therapy is an 3 
approach whereby human fibroblasts transplanted onto the posterior sclera may strengthen the sclera 4 
by producing type I collagen, and has been shown to significantly reduce axial elongation in a rat 5 
myopia model.[45]  6 
 7 
Conclusion: 8 
There is currently no definitive evidence to suggest that myopia control in childhood could prevent 9 
PM development later in life, and as such, long-term prospective studies are needed to answer this 10 
question. Research in myopia treatment would benefit from a shift in focus towards devising clinical 11 
therapies targeted at preventing AL elongation and PM. However, there is currently insufficient 12 
evidence to support a primary site of pathology in PM. Thus research into possible strategic targets 13 
for therapies may require focus on multiple sites, as current evidence suggest the possibility of 14 
Bruch’s membrane, choroid and sclera all playing a role in PM development.  15 
 16 
Controversy 2: There is currently no “gold standard” intervention in the clinical management 17 
of myopia control.  18 
 19 
Atropine eyedrops, orthokeratology, defocus multizone soft contact lens[46] and defocus incorporated 20 
multiple segments (DIMS) spectacle lenses[47] have been reported to be effective options for 21 
reducing myopia progression. Soft contact lenses and DIMS spectacles are recent innovations that 22 
have shown great promise for myopia control. A 3 year randomized clinical trial of MiSight dual 23 
focus contact lens (CooperVision, Pleasanton, CA, USA) (n=109) showed that myopia progression 24 
and axial elongation were 59% and 52% less in the MiSight arm than the single vision contact lens 25 
arm.[46] In the 2 year randomised clinical trial of DIMS spectacles (n=160), children on DIMS 26 
spectacles had significantly slower myopia progression and axial elongation (52% and 62% 27 
 9 
respectively) over 2 years when compared with those wearing single vision spectacle lenses. [48] 1 
However, variations between studies and individuals are large in the former and only one study in the 2 
later, further studies is warranted. There is also growing interest in combining pharmaceutical and 3 
lens based interventions.[49] A recent study (n=60) evaluated the efficacy of atropine 0.01% eyedrops 4 
as an adjunctive treatment for children who have already been on ortho-k treatment for a year.  While 5 
on Ortho-k treatment in the first year, axial elongation was 0.46 ± 0.16 mm/yr, decreasing 6 
significantly to 0.14 ± 0.14 mm/yr (p<0.001) when atropine was added in the second year.[50]  The 7 
potential synergistic effects from combination therapy may be of benefit particularly for rapid myopia 8 
progressors 9 
 10 
These treatment options are usually offered to patients based on the expertise of the eye care 11 
professional, influenced by a wide range of practice patterns around the world.[6] However, the 12 
clinical management of myopia ideally should be evidence-based, selected to provide the best risk-13 
benefit profile for that individual or child. Recently, two interventions have emerged with greatest 14 
potential for myopia control:  15 
‘Should orthokeratology be the treatment of choice for controlling myopia progression in children?’ 16 
Orthokeratology (Ortho-K) has been reported to be effective in controlling myopia progression (30-17 
56% reduction)[51-56] Ortho-K may have different treatment effects depending on the age and degree 18 
of myopia. In the Retardation of Myopia in Orthokeratology (ROMIO) study, the effectiveness of 19 
ortho-k on myopia control was observed to be better in younger children less than 9 years than in 20 
older subjects.[56]  In another retrospective study, AL elongation was slower by 49%, 59% and 46% 21 
in the low, moderate and high myopia subgroups respectively. While significant differences between 22 
orthokeratology and control groups were observed in both the first and second year of follow up in the 23 
low and moderate myopia groups, a significant difference was only observed in the first year within 24 
the high myopia group.[57] In comparison,  atropine’s efficacy depending on concentration, ranges 25 
between 60 to 80% reduction.[15-17 58-60]. However, higher doses are associated with increased side 26 
effects such as photophobia and a decrease in accommodation amplitude which may result in the need 27 
 10 
for photochromic, progressive or bifocal addition spectacles. Furthermore there is a need for 1 
concurrent spectacle or contact lens usage.[59]  On the other hand, the main risk associated with 2 
Ortho-K would be infectious keratitis. While the estimated incidence of infectious keratitis in Ortho-K 3 
wearers is rare at 7.7/10000 patient eye years, this increases to 13.9/10,000 patient-years in children, 4 
which make up the brunt of Ortho-K wear for myopia progression treatment.[61 62] A 10-year 5 
retrospective study of 104 eyes of 53 children who underwent orthokeratology treatment observed 6 
adverse events in 53 eyes (51%). Of these, conjunctival complications such as allergic conjunctivitis 7 
were the most frequent, while corneal infiltration and keratitis occurred in 8 eyes (7.7%).[63]  To put 8 
the figures in perspective, the estimated incidence of infectious keratitis in daily-wear rigid-gas-9 
permeable (RGP) lens wearers is 1.2/10,000, while in extended wear soft lens wearers, the incidence 10 
ranges from 13.3 – 19.5/10,000. This suggests that Ortho-K wear risk in children is essentially similar 11 
to that of extended wear soft contact lens wear.[64]  Risk factors for infectious keratitis include 12 
overnight wear, insufficient training of practitioners and wearers, non-professional fitting procedures, 13 
poor compliance with lens hygiene, or inadequate follow-up.[65] These infections can be severe and 14 
may result in visual loss or the need for corneal transplantation.  Importantly, parents should be 15 
counseled as to the risk of infectious keratitis and eye care professionals should undergo rigorous 16 
training and accreditation before prescribing Ortho-K to ensure quality control. Besides microbial 17 
keratitis, other side effects of Ortho-K include induced astigmatism, third and fourth order spherical 18 
aberrations, recurrent corneal erosion, corneal staining, edema and haze.[61 62] 19 
 20 
Rebound upon discontinuation is an important issue emphasized in atropine but this has been less 21 
widely studied in Ortho-K.[16 58 66] In terms of vision, Ortho-K provides the best uncorrected visual 22 
acuity, whereas atropine may cause poor near visual acuity especially with higher doses and 23 
spectacles are still required.  Quality of life and subjective ratings from multiple studies show an 24 
improvement with Ortho-K compared to wearing single vision spectacles.[67-69] The cost 25 
effectiveness of Ortho-K requires further study. Ortho-K lenses in general are more expensive than 26 
other optical interventions, costing annually on an average, USD$1000-2000[70], requiring 27 
 11 
individualised design and fitting, and intensive review to detect complications. Additionally, they are 1 
usually not covered by most health reimbursement or insurance plans.[70]  2 
 3 
‘Should atropine eye drops be used in children with low or no myopia to prevent myopia 4 
progression?’ 5 
Both the Meta-analysis of Interventions for Myopia Control (30 RCTs. 5,422 eyes) and the Meta-6 
analysis of Atropine Studies for Myopia Control (19 studies, 3,137 children) concluded that atropine 7 
markedly slowed myopia progression.[60] [59]  While there is currently only one small study 8 
providing evidence for the effectiveness of atropine in children with no myopia[71], it is known that 9 
younger age of myopia onset is associated with high myopia. It can be safely predicted that 5-year-old 10 
children, whose refraction are between +0.75D to -0.49D will soon develop myopia. These may be 11 
the at-risk group (pre-myopes) that is likely to benefit from low dose atropine use. ATOM3 is an 12 
ongoing double-blind randomized placebo-controlled clinical trial initiated in June 2017 to evaluate 13 
the use of atropine 0.01% in the prevention and control of myopia in pre-myopes.[72] 14 
 15 
The main concern against using atropine in children with no myopia is the risk of side effects.  In the 16 
LAMP study, 30-34% of children on atropine required photochromatic glasses and 2.8-6.4% 17 
developed allergic conjunctivitis.[18] 70% and 61% of subjects receiving 0.5% and 0.1% atropine, 18 
respectively, requested progressive glasses for reading in the ATOM 2 study.[16]  In the LAMP 19 
study, even 0.01% atropine was associated with accommodation paralysis in 1.8% of subjects.[18]  20 
Hence, some children may paradoxically require spectacles after commencing atropine. Although 21 
extremely rare, there is a risk of more severe systemic side effects such as palpitations, confusion, dry 22 
mouth and high fever.  In addition, the long term side effects of atropine eyedrops are still unclear. In 23 
children, a rebound effect was observed upon abrupt cessation of treatment, where the rate of myopia 24 
progression increased. When higher atropine was stopped for 12 months after 24 months of treatment 25 
(phase 2 of ATOM2), there was a rapid increase in myopia in children originally treated with higher 26 
concentrations of atropine, whereas those receiving the lowest concentration of 0.01% showed 27 
 12 
minimal change.[16 66] This rebound phenomenon can significantly reduce the effectiveness of 1 
atropine eyedrops for myopia control, compared to optical treatments. Importantly, atropine is largely 2 
used as an off-label treatment for myopia in most countries. Where low dose atropine eyedrops 3 
unavailable commercially, the use of low dose atropine may bear significant risks from patients 4 
diluting down higher doses and inconsistencies from compounding pharmacies.  5 
 6 
Conclusion:  7 
Overall, optimizing the clinical management of myopia would benefit from an alignment of best 8 
practice patterns, with a tailored approach that can only be achieved with close collaboration amongst 9 
eye care practitioners. While current evidence suggests that low-dose atropine is a good option, 10 
potential side-effects and the lack of availability in certain healthcare settings needs to be considered. 11 
However, the use of atropine in children with low or no myopia requires further evidence from 12 
clinical trials prior to any recommendation. There are other emerging treatment options that are 13 
effective such as orthokeratology, contact lens, and spectacles, which should be considered in the 14 
holistic management pathway of myopia. Finally, there is growing interest in combining 15 
interventions,[49] such as atropine and orthokeratology which may have a synergistic effect while 16 
balancing the risks and benefits of both therapies.[50] 17 
 18 
 19 
Controversy 3: Current technology is inadequate for the diagnosis and monitoring of myopia 20 
related complications.  21 
 22 
 23 
The burden of visual impairment arising from myopia comes primarily from PM and its complications 24 
such as MMD, which is now a leading cause of blindness in developed nations.[73] Thus, the early 25 
detection and monitoring for myopia-related complications is important for timely intervention and 26 
prevention of visual impairment.[74] The detection and evaluation of two major complications of PM, 27 
myopic choroidal neovascularisation and myopia-associated optic neuropathy, are discussed: 28 
 29 
 13 
‘Is optical coherence tomographic angiography (OCTA) adequate for the evaluation of myopic 1 
choroidal neovascularisation?’ 2 
Optical coherence tomographic angiography (OCTA) is a relatively new imaging technology that has 3 
emerged as a potential alternative to more invasive imaging modalities, namely fundus fluorescein 4 
angiography (FFA) for the evaluation of myopic choroidal neovascularisation (CNV). The pooled 5 
diagnostic accuracy of OCTA was reported in 2 separate meta-analyses to have a sensitivity of 0.87-6 
0.90, specificity of 0.97 and an area under the curve of 0.96 for detecting CNV.[75 76] OCTA, in 7 
conjunction with OCT, can be utilized for the monitoring of treatment response and activity. On OCT, 8 
the resolution of subretinal hyper-reflective material, subretinal fluid and a well-defined border to the 9 
CNV lesion are reliable signs of inactivity. On OCTA, the CNV lesion typically decreases in size 10 
although the vascular network persists, regular monitoring of the vascular network size on OCTA is 11 
useful for assessing for recurrence.[74] 12 
 13 
However, several limitations of OCTA remain. First, OCTA informs of perfusion through the 14 
vascular complex but offers no information on vascular leakage, which is a key treatment indicator.  15 
Relying on OCTA alone may result in over-treatment of inactive mCNV. Second, artefacts and poor 16 
scan quality are common in patients with poor vision and who are thus unable to sustain fixation long 17 
enough for scan acquisition. Third, segmentation errors are particularly prevalent in highly myopic 18 
eyes with long axial lengths, steep retinal contours and posterior staphyloma. Moreover, poor fixation 19 
and motion artefacts are common causes of uninterpretable scans (Figure 2).  20 
 21 
‘Can current diagnostics adequately diagnose and monitor glaucoma or myopia-associated optic 22 
neuropathy in high myopes?’ 23 
There are several challenges for the adequate diagnosis and monitoring of glaucoma or myopia-24 
associated optic neuropathy in high myopes.  Anatomically, the three layers of the optic nerve head, 25 
namely the BM opening, the choroidal opening, and the opening in the peripapillary scleral flange 26 
covered by the lamina cribrosa get misaligned by a shift of the BM opening usually into the temporal 27 
 14 
inferior direction.[77]  This leads to an overhanging of BM into the intrapapillary region at the nasal 1 
disc border, and to an absence of BM in the temporal parapapillary region, i.e. the temporal gamma 2 
zone.[77 78] With an axial length of more than 26.5mm, the BM opening additionally enlarges, 3 
eventually leading to a circular gamma zone, In addition, the colour contrast and spatial contrast 4 
between the optic cup and neuroretinal rim decrease with longer axial length.  This complicates the 5 
assessment of cup to disc ratio and measurements of retinal nerve fibre layer (RNFL) thickness with 6 
OCT.  Functionally, these eyes often have macular pathology and these may confuse the assessment 7 
of glaucomatous visual field defects on perimetry.  The decreased scleral rigidity in highly myopic 8 
eyes may also result in underestimation of the intraocular pressure in these eyes.[79 80] 9 
 10 
Regardless, there are clinical indicators and clues that can aid a physician in diagnosing and 11 
monitoring glaucoma in these patients.  First, glaucoma is a progressive disease in which longitudinal 12 
analysis is key. By comparing the same eye over time, the impact of ambiguous anatomy on diagnosis 13 
and monitoring will be reduced.  Second, assessing the macular ganglion cell-inner plexiform layer 14 
(GC-IPL) thickness measurements in areas without BM defects for vertical asymmetry is also a useful 15 
method for diagnosis and monitoring glaucoma because most eyes with MMD tend to have 16 
preservation of the inner retinal thickness at least in the earlier stages.[81]   17 
 18 
However, none of the current imaging modalities currently used for glaucoma assessment has been 19 
optimized for use in high myopes. RNFL measurements with OCT is problematic due to an indistinct 20 
BM edge which tends to shift temporally in high myopes.  The superior and inferior RNFL converge 21 
more temporally than in a non-highly myopic eye, and signal loss around optic disc can occur in the 22 
presence of a posterior staphyloma. GC-IPL measurements can be inaccurate when there is co-23 
existing myopic traction maculopathy (Figure 3) or underlying BM defects. An overarching 24 
limitation of structural analysis is the lack of a normative database for the highly myopic population, 25 
which is likely to differ significantly from a database of non-highly myopic eyes due to the above-26 
mentioned anatomical differences. Lastly, objective visual field assessment such as the Humphrey 27 
 15 
Visual Field (HVF) is often unable to differentiate between deterioration due to glaucoma or myopic 1 
maculopathy.[79 82] 2 
 3 
Conclusion:  4 
The structure of the myopic eye adds complexity to the evaluation and early detection of sight 5 
threatening complications such as MMD and myopia-associated optic neuropathy, that cannot be 6 
bridged with current diagnostics. Collaboration between clinicians, researchers and industry is needed 7 
to optimize diagnostic and imaging technologies specifically for the myopic eye. Currently, OCTA 8 
imaging alone may be inadequate for evaluating myopic CNV, while the evaluation of myopia-9 
associated optic neuropathy requires further research to accurately evaluate optic nerve damage in 10 
PM. Overall, there is an unmet need to explore and develop new imaging modalities for both 11 
structural and functional analyses and to establish normative databases for myopia in the long term. 12 
 13 
Summary and Conclusions 14 
The aim of this review is to highlight various aspects of clinical myopia discussed during the 15 
International Myopia Summit in 2019, including gaps in myopia research that require further study, 16 
consensus where evidence is not well established, and a call to action for stakeholders to collaborate 17 
in the management of myopia. We acknowledge that the views presented are limited to that of the 18 
workgroup, which comprised an international panel from diverse backgrounds, all involved in myopia 19 
prevention or research. There are also potential biases arising from the representation of myopia 20 
experts mainly from Asia, but we have included a comprehensive review of the available published 21 
evidence to provide an objective summary in this article. Nonetheless, we have highlighted three key 22 
areas with regards to the clinical management of myopia, which may benefit from further research 23 
and development. First, controlling childhood myopia is theoretically preventing futher high myopia 24 
in adulthoor. However, as controlling childhood myopia alone may not be enough to prevent the 25 
development of PM in adulthood, there is an unmet need to search for potential treatment targets and 26 
to develop therapies interventions that prevent progression to PM. Second, the clinical management of 27 
 16 
myopia will benefit from co-management from eye care professionals, such that the treatment plan 1 
may be tailored to patient needs while weighing the relative costs and benefits of each intervention. 2 
Third, evaluation of myopia complications using current technologies present limitations that require 3 
collaboration between clinicians, researchers and industry partners to overcome in the long term. The 4 
workgroup advocated a paradigm shift in our approach to clinical management of myopia - one that 5 
necessitates coordinated action among the eye care community in our fight against the ‘myopia 6 
epidemic’.  7 
 8 
 9 
Supplementary Table 1: A summary of debated topics and consensus achieved at the International 10 
Myopia Summit  11 
 12 
Motion Consensus 
Myopia Prevention and Public Policy 
Are current myopia definitions to inform 
public policy currently adequate? 
There is overemphasis on cut-off values for 
myopia. Myopia as a refractive error is a 
continuous measure with multifactorial risk for 
developing complications.[12 83]  
Should myopia be a primary priority for 
health ministries in Asia? 
Advocates require more data on cost effectiveness 
and societal impact, (which includes workforce 
productivity, education and national defense), to 
justify and empower ministries to act.[84-96] 
Should outdoor time be mandated for all 
school-going children? 
This is considered the most cost-effective myopia 
prevention strategy, but there are challenges in its 
implementation. There is a need to engage 
stakeholders, such as parents, health and 
 17 
education ministries to address these 
challenges.[87 97-100]   
Myopia Control 
Should “breaks” in near work activities be 
mandated for all school-going children? 
More evidence is needed to support this 
intervention. The causal relationship between 
myopia and near work, the relative contribution of 
near work vs outdoor activity, and the effect of 
different types of near work on myopia require 
further study.[101-107] 
Is orthokeratology the treatment of choice 
for controlling myopia progression in 
children? 
Careful patient selection and stringent follow up 
with close co-management between optometrists 
and ophthalmologists are important to maximize 
efficacy and minimize the risk of blinding 
complications.[51-61 63-70] 
Should atropine be used in children with 
low or no myopia to prevent myopia 
progression? 
Low dose atropine is effective for myopia control 
in children with low myopia, but the exact dosage 
to minimise side effects whilst retaining efficacy 
is still to be determined. Further evidence from 
clinical trials for the safety and efficacy of low 
dose atropine in children without myopia is 
needed.[16 18 59 60 66 71] 
Myopia myths 
Are environmental factors more important 
than genetics as a determinant of myopia? 
The effectiveness of environmental interventions 
should be considered in the context of different 
genetic risk determinants.[108-112] 
Are near work and increased screen time 
related to myopia progression? 
Near work is related to myopia onset and 
progression, but this is less clear for increased 
 18 
screen time. More studies are needed to 
investigate the effect of increased screen time on 
increased near work and reduced time spent 
outdoors.[98 102 113 114]  
Does controlling myopia in childhood 
prevent pathologic myopia in adulthood? 
Pathologic myopia is a multifactorial disease with 
additional risk factors besides refractive error, 
such as age, gender and genetics.  Controlling 
refractive error alone may not be enough to 
prevent pathologic myopia.  Long term studies are 
needed to assess the effectiveness of myopia 
control in childhood on the prevention of 
pathologic myopia in adulthood.[10-27] 
Industry and regulation of myopia treatment 
Should spectacles be reimbursed by health 
insurance and/or public health care 
providers? 
WHO has included spectacles in the list of 
Priority Assistive Products, and spectacle 
coverage is now an indicator for Universal Health 
Coverage.  However, there are barriers to 
implementation that need to be overcome, 
including the lack of integration of refractive and 
optical services in health systems, regulatory 
hurdles and issues of equitability.[115] 
Should orthokeratology be regulated as a 
medical device? 
Orthokeratology is regulated as a medical device 
by many government agencies. More stringent 
regulations may be required, such as a 
requirement for eyecare professionals to be 
trained and certified before they can prescribe 
orthokeratology. Co-management between 
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optometrists and ophthalmologists is important to 
minimize the risk of complications such as 
corneal infections.[62 116 117] 
Should refractive surgery be considered a 
medical treatment for adult high myopia? 
Refractive surgery should not be considered a 
medical treatment because of issues with efficacy 
and predictability of excimer laser treatments, side 
effects of phakic intraocular lenses, risk of 
malpractice litigation and lack of evidence for 
cost effectiveness compared to spectacles or 
contact lenses.[118-122]  
Pathologic myopia 
Is wide field imaging mandatory to screen 
for pathologic myopia in adult high 
myopes? 
The cost, affordability, quality and accuracy of 
wide field imaging requires further study. Wide 
field imaging cannot replace good history taking 
and a dilated fundal examination. Guidelines on 
who to screen and what to screen for are 
needed.[123 124] 
Is retinal detachment in high myopes best 
managed with combined scleral buckling 
and vitrectomy? 
High myopes with rhegmatogenous retinal 
detachment are typically younger, phakic patients 
that can be adequately managed with scleral 
buckling alone.  In more complex cases requiring 
vitrectomy, adding an encircling scleral buckle to 
support the vitreous base may optimise single 
surgery success rates.[125-128]  
Should myopic traction maculopathy be 
treated early before vision deteriorates? 
There is significant risk of visual loss from 
macular hole associated with surgery for myopic 
traction maculopathy.  Surgery should be reserved 
 20 
for patients with foveal detachment or worsening 
vision, and monitoring is advised for patients with 
early stages of myopic traction maculopathy.[129-
133] 
 
Is optical coherence tomographic 
angiography adequate for starting treatment 
in and monitoring of myopic choroidal 
neovascularisation? 
The structural abnormalities of the highly myopic 
eye present significant difficulty for current 
imaging technology, including optical coherence 
tomographic angiography.  Collaboration between 
clinicians, researchers and industry partners is 
needed to improve and optimize imaging 
modalities for the myopic eye.[74-76]  
Is Bruch’s membrane the primary site of 
pathology in pathologic myopia? 
There is insufficient evidence to support a primary 
site of pathology in pathologic myopia. Further 
research is required to elucidate the pathogenesis 
to guide the development interventions for 
pathologic myopia.[28-32 35-42]  
Can glaucoma in high myopes be 
adequately diagnosed and monitored with 
current diagnostics? 
There is a need to explore and develop other new 
imaging modalities and to build normative 
databases for both structural and functional 
analyses.  This requires close collaboration 




Supplementary table 2: Organisations represented at the International Myopia Summit Workgroup 3 
2019. 4 
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Organisations  1. World Health Organisation (Western Pacific Region) 
2. International Agency for Prevention of Blindness  
3. International Myopia Institute 
4. World Optometry Council 
5. Centre for Eye Research Australia, Australia  
6. Brien Holden Vision Institute, Australia  
7. School of Optometry and Vision Science, University of New South Wales  
8. School of Optometry and Vision Science, Queensland University of 
Technology, Australia 
9. Research School of Biology, Australian National University, Australia 
10. Shanghai Eye Diseases Prevention & Treatment Centre, China  
11. Department of Ophthalmology, Wenzhou Medical College, China  
12. Medical Faculty Mannheim, Heidelberg University, Germany  
13. Singapore Eye Research Institute, Singapore  
14. National University Hospital, Singapore 
15. National Healthcare Group Eye Institute, Singapore  
16. Institute of Molecular and Cell Biology (IMCB), Agency for Science, 
Technology and Research (A*STAR), Singapore 
17. Kaohsiung Chang Gung Memorial Hospital, Chinese Taipei  
18. Chang Gung University College of Medicine, Chinese Taipei  
19. International Centre for Eye Health, London School of Hygiene and Tropical 
Medicine, United Kingdom  
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Figure legends 1 
Figure 1: The future of research in myopia. 2 
Figure 2: 12x 12mm Swept source optical coherence tomographic angiography scans of the choroid in 3 
a patient with good fixation (A) and a patient with poor fixation (B) Note the presence of motion 4 
artefacts (white arrowheads) and artefactual dropout of vascular flow signal due to from segmentation 5 
error (white arrow). 6 
Figure 3:  Ganglion cell- inner plexiform layer (GC-IPL) thickness analysis using spectral domain 7 
optical coherence tomography (SD-OCT) in a patient with high myopia and normal tension glaucoma.  8 
Red and yellow lines on the OCT B scan image define the anterior and posterior boundaries of the 9 
GC-IPL layer respectively. Segmentation error is seen on the OCT B scan in the right eye (white 10 
arrow) due to myopic traction maculopathy. 11 
 12 
